Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1996;27:1236-1240

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wasterlain, C. G.
Right arrow Articles by MacManus, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wasterlain, C. G.
Right arrow Articles by MacManus, J.

(Stroke. 1996;27:1236-1240.)
© 1996 American Heart Association, Inc.


Articles

Felbamate Protects CA1 Neurons From Apoptosis in a Gerbil Model of Global Ischemia

Claude G. Wasterlain, MD; Lisa M. Adams; Joseph K. Wichmann, PhD R. Duane Sofia, PhD

the Department of Neurology and Brain Research Institute, VA Medical Center at Sepulveda, University of California-Los Angeles School of Medicine (C.G.W., L.M.A.); and the Preclinical Research Department, Wallace Laboratories, Inc, Cranbury, NJ (J.K.W., R.D.S.).

Correspondence to Claude G. Wasterlain, MD, Neurology Service (127), VA Medical Center, Sepulveda, CA 91343-2099.

Background and Purpose Felbamate, a novel anticonvulsant that binds to the glycine site of the N-methyl-D-aspartate receptor, has been shown to have neuroprotective properties in vitro and in vivo. In a rat pup model of hypoxia-ischemia, felbamate selectively reduced delayed death in hippocampal granule cells. The present study explores its neuroprotective potential in a gerbil model of global ischemia, in which good evidence exists that ischemia triggers apoptosis of CA1.

Methods Gerbils were subjected to bilateral carotid occlusion for 5 minutes and then treated with felbamate (100 or 200 mg/kg IV) or vehicle. They were killed 3 days later, and the numbers of live and dead neurons in the CA1 sector of the hippocampus were counted at stereotaxically defined levels.

Results Felbamate (200 mg/kg IV) administered after the release of carotid clamping did not change brain temperature but reduced neuronal death in CA1 from 332±60 cells per section of dorsal hippocampus in unmedicated gerbils to 62±12 cells in felbamate-treated animals (P<.001). A lower dose of felbamate (100 mg/kg post hoc) showed only a nonsignificant reduction of neuronal death. In the 200-mg/kg group, felbamate serum concentrations peaked at 162 µg/mL and were above 100 µg/mL for at least 3 hours, and brain levels reached 150 µg/mL at 1 hour. In the 100-mg/kg group, blood serum levels were well below 100 µg/mL.

Conclusions These results suggest that felbamate given post hoc is remarkably effective in preventing delayed apoptosis secondary to global ischemia but that effective neuroprotection requires doses higher than those used for anticonvulsant treatment.

Editorial Comment

John MacManus, PhD, Guest Editor

Apoptosis Research GroupInstitute for Biological SciencesNational Research Council of CanadaOttawa, Ontario, Canada